TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: 2 year relapse-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Mean global score of nasal symptoms
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Delivery outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in number of IOP lowering drugs
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: AUC(0-48) of levocetirizine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adjusted Mean Change From Baseline in Evaporative Sensitivity Pain Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: β cell function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Local disease control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants with EEG alterations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in number of leakage episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Longitudinal median nerve excursion with neck flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Longitudinal median nerve excursion with ipsilateral neck rotation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of readmissions due to severe dehydration
Endpoint domain: Adverse events/effects
Primary endpoint: Change in serum melatonin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in incontinence episode frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk prediction of Coronary Artery Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CAPS-5 Total Severity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Target Frontal-parietal Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Working Memory Performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: patient-reported disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Changes in Pressure Pain Thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Conditioned Pain Modulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of hyperparathyroidism (HPT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Prevalence of hypercalcemia (hypercalcemic hyperparathyroidism)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Identification of specific circulating proteins (biomarkers) of inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Macroscopic characterization of tissue inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microscopic characterization of tissue inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coagulation markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Vascular markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Microparticles level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Maximum Glucose Infusion Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: time of culture to reach the maximal expansion factor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of cells alive
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentages of CD4- iNKT cells capable of producing IFN-γ after expansion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: rate of ductal closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Immediate and Delayed Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Discontinuation from the study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in forced expiratory value in 1 second
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: time till the first cardiovascular composite endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: In-Brain Distant Failure Rate
Endpoint domain: Mortality/survival
Primary endpoint: Best Corrected Visual Acuity Change From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retinal Thickness Change From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of childbirth by low way
Endpoint domain: Mortality/survival
Primary endpoint: Change in Score on Child Depression Rating Scale - Revised (CDRS-R)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: change in the mean of BUN, serum Cr, serum K and serum phosphorus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change in interdialytic weight gain (IDWG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of adverse events/adverse device effects
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Lymphadema Grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Percentage of Participants With Composite Efficacy Endpoints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients willing to be randomized
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of enrolled patients lost to follow up
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Completion rate for satisfaction survey
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of subjects with Clinical Adverse Events (CAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects with Serious CAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects with drug-related CAEs
Endpoint domain: Adverse events/effects
Primary endpoint: type specific antibody titers for HPV types 6, 11, 16 and 18
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Efficacy of NT-KO-003
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Post-traumatic stress disorder symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Percentage Change in Symptom Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Patients Experiencing Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Cognitive Measure
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Functional Measure
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Behavioral Measure
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in 18F-Fluorothymidine (FLT) Uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Grade 3 or 4 Solicited Local Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Grade 3 or 4 Solicited Systemic AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Sustained Viremic Control (HIV RNA <50 Copies/mL) During ATI Phase
Endpoint domain: Adverse events/effects
Primary endpoint: Occludin level expression in left colonic biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Faecal calprotectin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Subjects With HBV DNA <1000 IU/ml at Week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants With HBV DNA <1000 IU/ml at Week 192
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Infertility Stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Life Quality Scale for Persons with Fertility Problems
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Child FAQLQ global score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Baseline measurement of qSOFA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post Transplant Reduction in Viral Load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Indocyanine Green levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Foot and Ankle Ability Measure
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Response rate (CR or PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 3 or greater toxicities assessed using CTC version 2.0
Endpoint domain: Adverse events/effects
Primary endpoint: Behavioral approach test (BAT) - generalization context
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Behavioral approach test (BAT) - treatment context
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Heights Interpretation Questionnaire (HIQ)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Participants Who Complete 24 Weeks of Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: CTCAE v4.0 higher than grade 2
Endpoint domain: Adverse events/effects
Primary endpoint: Incremental Post-prandial 4-hour Weighted Mean Active GLP-1 Plasma Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Pathological T stage of disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of Subjects Who Receive and Tolerate a VIVITROL Injection
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Bisect offset index (BOI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Patellar tilt angle (PTA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Lateral patellofemoral angle (LPFA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Lateral patellar displacement (LPD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Seroprotection Rate of HI Antibody Titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Tissue effects of FloSeal upon endometrium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: selective-spatial attention
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: executive attention - conflict resolution
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Phase aberration correction of skull bone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Frequency of Incontinence Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse Event Reporting
Endpoint domain: Adverse events/effects
Primary endpoint: Irisin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BMI development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 6-months progression-free survival (PFS) rate
Endpoint domain: Mortality/survival
Primary endpoint: Binding rate to cerebral receptors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of units of plasma collected
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Accuracy of electronic blood pressure monitor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Patient temperatures recorded
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Portal blood flow estimation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Late adverse gastrointestinal or genitourinary events grade 3 or higher
Endpoint domain: Adverse events/effects
Primary endpoint: Clearance of ceftazidime
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Visual Attention Performance Speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Mean Severity of Proximal Stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Rate of venous thrombolic events
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of major bleeding events during treatment phase
Endpoint domain: Adverse events/effects
Primary endpoint: No device related reoperation
Endpoint domain: Adverse events/effects
Primary endpoint: Detection accuracy change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Opioid requirement in first 24 hours after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Anatomical distribution of [18F]F-AraG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Dyspnea Numeric Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hot Flush Frequency Total Score (HFRS) Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Menopause Rating Scale (MRS) Score Change
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: First procedure stone clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Foot strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Regain of GIT motility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Postoperative peripheral neuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Geometric Mean Peak Plaque Reduction Neutralization Titer (PRNT) After Second Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Reporting Moderate or Severe Solicited Local Injection Site Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Change in Spherical Equivalent Refractive Error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HSV-2 incidence
Endpoint domain: Adverse events/effects
Primary endpoint: postoperative parathyroid hormone level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Gait Profile Score (GPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Gait deviation index (GDI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Gait speed (metre/sec)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Cadence (steps/ minute)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep Start Time
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Sleep End Time
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Recurrence of cerebral infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Safety of escalating doses
Endpoint domain: Adverse events/effects
Primary endpoint: Change in diastolic properties
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Low Back Pain Responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Pharmacokinetic parameters (AUC, Cmax, Cmin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Critical respiratory events requiring Naloxone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: rates of laboratory-confirmed influenza in vaccinated and unvaccinated pregnant women
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: rates of laboratory-confirmed influenza in young infants whose mothers were vaccinated and in infants of unvaccinated mothers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Diabetic foot ulcer risk score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Time Spent in Euglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Concentration of patient anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of length of hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of Participants with re-admission after discharge
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Success rate of laryngomicrosurgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in the Goodman and Baron score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of clinical symptoms of HED/XLHED at birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in PANSS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Mean Ambulatory Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Adverse Events/Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical Global Impression of Severity (CGI-S AD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: protein-bound toxin removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: low-molecular weight protein removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: small solute removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Dizziness Handicap Inventory (DHI)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in miniBEST test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Community-simulated Ambulatory Task (CAT)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Passive Angular Vestibular Reflex Testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Receipt of further treatment for an eating disorder
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Bowel dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Index of sympathetic block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Epiphora Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lacrimal Passage Irrigation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Changes in Free Serum IgE Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Trimus measured by interincisal distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Swelling measured by The Laskin method
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Parotid Salivary Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 28-days ICU mortality
Endpoint domain: Mortality/survival
Primary endpoint: Glu levels within the insula and thalamus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in Activities of Daily Living (ADL)-functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Agreement of Macular Thickness Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement of Retinal Nerve Fiber Layer Thickness Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement of Corneal Thickness Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numerical rating scale (NRS) rated by surgeon
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Impact of chronic diseases
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: time to malignant recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants With a ≥ 50% Decrease in Headache Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Recurrence of heroin dependence
Endpoint domain: Adverse events/effects